Table 1 Correlation between miR-1249 expression and different clinical characteristics

Gender

0.072

 Male

74 (66.1%)

32 (57.1%)

42 (75.0%)

 Female

38 (33.9%)

24 (42.9%)

14 (25.0%)

Age (years)

0.156

 <60

36 (32.1%)

14 (25.0%)

22 (39.3%)

 ≥60

76 (67.9%)

42 (75.0%)

34 (60.7%)

Tumor location

0.130

 Colon

59 (52.3%)

34 (60.7%)

25 (44.6%)

 Rectal

53 (47.7%)

22 (39.3%)

31 (55.4%)

TNM stage

<0.001

 I–II

65(58.0%)

43(76.8%)

22 (39.3%)

 III–IV

47(42.0%)

13(23.2%)

34 (60.7%)

Differentiation

0.727

 Low

27 (24.1%)

12 (21.4%)

15 (26.8%)

 Moderate

70 (62.5%)

37 (66.1%)

33 (58.9%)

 High

15 (13.4%)

7 (12.5%)

8 (14.3%)

pT stage

0.237

 T1–T2

13 (11.6%)

4 (7.1%)

9 (16.1%)

 T3–T4

99 (88.4%)

52 (92.9%)

47 (83.9%)

pN stage

0.009

 N0

66 (58.9%)

40 (71.4%)

26 (46.4%)

 N1

31 (27.7%)

11 (19.6%)

20 (35.7%)

 N2

15 (13.4%)

5 (9.0%)

10 (17.9%)

pM stage

0.003

 M0

96 (85.7%)

53 (94.6%)

43 (76.8%)

 M1

16 (14.3%)

3 (5.4%)

13 (23.2%)

Tumor size

0.336

 <5 cm

66 (58.9%)

30 (53.6%)

36 (64.3%)

 ≥5 cm

46 (41.1%)

26 (46.4%)

20 (35.7%)

CEA

0.554

 <10 ng/ml

72 (64.3%)

34 (60.7%)

38 (67.9%)

 ≥10 ng/ml

40 (35.7%)

22 (39.3%)

18 (32.1%)

CA199

0.255

 <10U/ml

51 (45.5%)

29 (41.1%)

22 (50.0%)

 ≥10U/ml

61 (54.5%)

27 (58.9%)

34 (50.0%)